Why Canopy Growth Withdraws Penelope, a Sustainable Medical Cannabis Strain
Canopy Growth Polska Withdraws Popular Medical Cannabis Strain Penelope Due to Quality Concerns.
Canopy Growth Polska is withdrawing its popular medical cannabis strain, Penelope (THC 8%, CBD 7%), due to aging genetics and quality concerns. While this decision may disappoint patients, the company is working on introducing new strains with similar profiles. This move underscores Canopy Growth’s commitment to quality and patient safety in the Polish medical cannabis market.
The context of the withdrawal of the Penelope variety
Canopy Growth Polska, part of the international Canopy Growth Corporation, has been providing Polish patients with high-quality medical products based on hemp for years. The company is a market leader, and its products are appreciated by both patients and doctors. The Penelope strain, characterized by a balanced content of the cannabinoids THC (8%) and CBD (7%), was one of the company’s flagship products, offering patients a unique combination of ingredients with therapeutic potential.
Penelope gained popularity thanks to its balanced cannabinoid profile, which is rare on the Polish market. The balanced content of THC and CBD made this strain preferred by many patients who needed support in treating various ailments, such as chronic pain, inflammation, as well as sleep problems or anxiety.
Reasons for Penelope’s withdrawal
The decision to discontinue Penelope was difficult but necessary for Canopy Growth Polska. The main reason for this decision is the aging of the strain, which has made it more susceptible to quality fluctuations. Over time, the genetics of the plant can weaken, which consequently leads to a decrease in the stability of the product. For a company whose priority is to provide the highest quality products, this was an unacceptable risk.
Canopy Growth Polska emphasizes that concern for quality and patient safety has always been and remains the top priority. The Penelope recall aims to prevent situations in which the quality of the product could no longer meet the high standards to which Polish patients and healthcare workers have become accustomed.
“The decision to discontinue Penelope was very difficult for us, as it is a strain that enjoyed huge interest. However, our commitment to providing only the highest quality products forced us to take this step,” says a representative of Canopy Growth Polska.
Canopy Growth Polska’s response and plans
Although the withdrawal of Penelope may be disappointing for many patients, Canopy Growth Polska does not leave them without support. Intensive work is already underway to introduce a replacement that will be characterized by a similar, balanced THC/CBD profile. The new variety that the company is working on is to not only meet, but even exceed the expectations of patients in terms of quality and effectiveness.
The company also announced the introduction of other medical strains that have a similar profile to Penelope. These products are expected to be available soon, allowing patients who have relied on the balanced effects of THC and CBD to continue their therapy.
“The process of registering new varieties of medical cannabis in Poland is time-consuming, but we are constantly working to provide patients with appropriate substitutes as quickly as possible. Our goal is to ensure continuity of therapy and support for doctors and patients,” adds the company representative.
The significance of the decision for the medical marijuana market in Poland
The withdrawal of Penelope from the market is a significant event for medical marijuana patients in Poland. This strain, due to its unique properties, was often the first choice for people starting cannabis therapy. Now they will have to look for alternatives, which can be a challenge, especially in the context of the lack of products with a similar profile on the market.
This decision may also affect the dynamics of the medical marijuana market in Poland. Other producers may start introducing strains with a similar composition to the market to meet the demand for products similar to Penelope. On the other hand, Canopy Growth Polska, through its announcements, is trying to maintain its leadership position by preparing new strains that are supposed to meet the needs of patients.
